All Type of News
Imbruvica & Vimizim registered for insurance benefits under special case system
A series of rare disease products that are applied by the special case system of economic evaluation will be registered for the health insurance benefit.
They are the Janssen’s mantle cell lymphoma treatment Imbruvi...
Targeted therapy developed by Hanmi, ‘Olita Tab’ approved as 27th domestic new drug
A Hanmi-developed targeted therapy for lung cancer acquired approval as the 27th domestic new drug.
The Ministry of Food and Drug Safety announced approval of the first domestically-developed targeted therapy for lun...
Celltrion’s Remsima announces dismissal of issuing ban suit of additional indication
Celltrion has started to enlarge its share in the Canadian market. On the 13th, Celltrion announced dismissal of the suit filed by Janssen to the Canadian court last September in regards to issuing ban of addition ind...
Speedy preparation on ‘preferential measures for new globally-expanded drugs’
The Ministry of Health and Welfare(MOHW) picked up speed on preparing preferential measures on drug price for new globally-expanded drugs.
The MOHW recently hold a working-level meeting for the Drug Pricing System Re...
KPA decides to strongly opposed to telemedicine dispenses and pharmaceutical parcel
The Korean Pharmaceutical Association(President Chan-hui Jo, KPA) held an emergency branch managers’ meeting at its chamber on the 13th, and shared opinions about the recent report that pharmacy-related matters, such ...
Doctors and dentists’ defenses, “Dentists cannot perform Botox procedures”
Doctors will stand for the grand courtroom at the Supreme Court. The Korean Medical Association(KMA) and Association of Korean Dermatologists(AKD) will make public defenses over illegality of the dentists’ Botox proce...
Establishment of joint committee for governmental antibiotic resistance management
The national-level antibiotic tolerance measure will be prepared to prevent super bacteria responses.
The Ministry of Health and Welfare(Minister Jin-yup Jung) will run a joint committee participated by medical organ...
CEOs of multinational pharmaceuticals’ Korean branches suffer
CEO of multinational pharmaceutical companies’ Korean branches, especially Korean CEOs, are going through sufferings. Only within this month, 3 Korean CEOs have either already left or is about to do so.
Although rel...
Olmesartan in crisis? Removal of discussion event schedule
The destiny of olmesartan – whose safety letter is distributed in Korea as removed from the insurance benefit by the French Agency for the Safety of Health Products(ANSM) due to suspicion in safety and validity – is e...
Domestic companies challenging Vesicare’s substance patent
On the 9th, Astellas Korea announced it filed a patent infringement prohibition suit over Vesicare jointly with its headquarters against CorePharm Bio to the Seoul Central District Court
Since no foreign pharmaceuti...
